PRDecoded and the Purpose Awards are almost here. Go here to find out more about the panels, agenda and network opportunities.

The newly approved treatment for ALS will cost $158,000 per year, though the maker of the drug, Amylyx Pharmaceuticals, said most patients will pay very little for it themselves. The drug will be marketed under the brand Relyvrio. 

The number of people worldwide with type 1 diabetes could double worldwide by 2040, according to a story published in Lancet Diabetes & Endocrinology. Research has estimated that more than 8 million people live with the disease globally.

Children’s hospitals are stripping information about the services they provide after a string of threats targeting those that provide gender-affirming care, and even those that don’t. Advocates say it could make it more difficult for transgender individuals to get care.